New scan could spot hidden prostate cancer
NCT ID NCT06840535
Summary
This completed Phase 1 study tested the safety and radiation exposure of a new imaging agent called 68Ga-OncoACP3 for prostate cancer. Twenty men with prostate cancer received a single injection followed by PET/CT scans to see where the tracer goes in the body and measure radiation doses to healthy organs. The goal was to gather initial safety data and see if this new tracer could help doctors better detect prostate cancer tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
ASST Papa Giovanni XXIII
Bergamo, BG, 24127, Italy
-
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Milano, 20133, Italy
-
IRCCS Ospedale San Raffaele
Milan, Milano, 20132, Italy
Conditions
Explore the condition pages connected to this study.